Artidis
Business Services · Switzerland · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Hochbergerstrasse 60c, Basel, Basel-City...Phone Number
+41 616332994Website
www.artidis.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
2
1
1
About Artidis
ARTIDIS is a pioneering company that utilizes a proprietary nanotechnology platform for tissue analysis, specifically aimed at improving cancer patient outcomes. Their innovative technology integrates mechanobiology to provide rapid cancer diagnosis, evaluate tumor aggressiveness, and predict metastasis likelihood, thereby personalizing treatment plans. By addressing the challenges of current cancer treatment optimization, ARTIDIS empowers clinicians and patients with precise diagnoses and effective therapy strategies. The ARTIDISNET platform combines nanomechanical biomarkers with clinical data to guide personalized therapy decisions, ultimately enhancing the quality of care in oncology.Explore more
Artidis Org Chart
ZT
Golang Developer
ES
Medical Device Software Engineer
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Artidis your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Artidis
Funding: Get notified immidiatlly once Artidis has new funding data
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Artidis had a recent Job posting/layoffs
Product Launch: Get notified when Artidis launches new products
Earning: See what the market has to say on Artidis recently announced quarterly report
Artidis, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Artidis is spiking on competitors!
Check if Artidis has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
Artidis is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Artidis is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Artidis.
Artidis financials insights
Gather financial insights about Artidis, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Angel/Seed
$8.8M
Artidis Tech Stack
A closer look at the technologies used by Artidis
Most Recent Scoops
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Event
Product Marketing, Events, Training, Sales, Search, Medical Research, Clinical Operations, Field Marketing, Healthcare Operations, Healthcare Technology, Operations, Radiology
Funding
Funding
Artidis News & Media
Former U.S. CDC Director joins Board of Swiss health technology company: ARTIDIS announces board appointment of Dr. Julie Gerberding, President and CEO of the U.S. Foundation for the National Institutes of Health (FNIH)
BASEL, Sept. 24, 2024 — ARTIDIS today announced the appointment of Dr. Julie Louise Gerberding to its Board of Directors, effective immediately. Dr. Gerberding is President and CEO of the Foundation for the National Institutes of Health (FNIH), a non-profit organization based in the United States that builds public-private-patient biomedical research partnerships to address important medical challenges in support of the NIH mission. ARTIDIS is a pioneering clinical stage tech company that aims tARTIDIS Announces Appointment of Dr. Ajit Singh, Ph.D. to Board of Directors
ARTIDIS Announces Appointment of Dr. Ajit Singh, Ph.D. to Board of DirectorsMD Anderson and ARTIDIS Announce Strategic Alliance to Advance Nanomechanical Technology Platform for Optimizing Cancer Treatment
Collaboration aims to provide clinical validation of the ARTIDIS platform for broad cancer applicationsHOUSTON and BASEL, Switzerland, Oct. 03, 2022 (GLOBE NEWSWIRE) -- ARTIDIS AG, the developer of the first nanomechanical technology platform for tissue analytics, and The University of Texas MD Anderson Cancer Center today announced a strategic alliance to investigate ARTIDIS technology as a novel treatment-optimization tool for patients with solid tumors in several distinct indications. SupportARTIDIS enters clinical collaboration to investigate nanomechanical profiling as a novel diagnostic and treatment optimization approach in patients with lung cancer
Basel, Switzerland, May 4, 2021 – ARTIDIS AG, a privately held health-tech company, announces a collaboration with Hospital Clínic de Barcelona and the University of Barcelona to investigate the ARTIDIS AFM technology as a novel diagnostic tool for patients with non-small cell lung carcinoma (NSCLC), the most frequent type of lung cancer. The research partners will identify biomarkers that will enable fast and accurate lung cancer diagnosis in a clinical bedside setting. Based on the
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Artidis
Sign Up For FreeTo access detailed company insights
ARTIDIS is a pioneering company that utilizes a proprietary nanotechnology platform for tissue analysis, specifically aimed at improving cancer patient outcomes. Their innovative technology integrates mechanobiology to provide rapid cancer diagnosis, evaluate tumor aggressiveness, and predict metastasis likelihood, thereby personalizing treatment p... Read More
